The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| NKTR | +186.02% | -76.52% | -25.16% | +10% |
| S&P | +14.5% | +93.32% | +14.09% | +1,379% |
Nektar Therapeutics is a global biopharmaceutical company focused on the discovery and development of novel therapies that selectively modulate the immune system to treat autoimmune disorders. It applies its deep understanding of immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly selective medicines with optimal therapeutic benefit.
Is it too late to get on the bandwagon?
Results of the Resolve-AD trial with rezpegaldesleukin were better than expected.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $11.18M | -52.4% |
| Gross Profit | $10.96M | -20.3% |
| Gross Margin | 98.09% | 39.6% |
| Market Cap | $320.59M | 40.8% |
| Market Cap / Employee | $5.26M | 0.0% |
| Employees | 61 | -55.5% |
| Net Income | -$41.59M | 20.6% |
| EBITDA | -$35.57M | -1.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $24.92M | 79.0% |
| Accounts Receivable | $0.00M | -100.0% |
| Inventory | 0 | -100.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $154.72M | -22.0% |
| Short Term Debt | $22.01M | 3.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -44.39% | -2.1% |
| Return On Invested Capital | -55.82% | -4.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$45.78M | -20.8% |
| Operating Free Cash Flow | -$45.74M | -21.3% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 4.91 | 2.84 | 9.21 | 23.34 | 1198.63% |
| Price to Sales | 2.92 | 2.02 | 1.64 | 4.86 | 74.76% |
| Price to Tangible Book Value | 73.58 | 52.64 | 31.20 | 23.34 | -13.43% |
| Enterprise Value to EBITDA | -7.01 | -5.66 | -2.54 | -10.26 | 73.30% |
| Return on Equity | -161.6% | -124.1% | -189.5% | -440.8% | 244.32% |
| Total Debt | $206.09M | $194.34M | $186.66M | $176.73M | -19.52% |
NKTR earnings call for the period ending September 30, 2021.
NKTR earnings call for the period ending June 30, 2021.
NKTR earnings call for the period ending March 31, 2021.
NKTR earnings call for the period ending December 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
